Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial - PubMed
6 hours ago
- #bradykinin receptor antagonist
- #hereditary angioedema
- #clinical trial
- Oral deucrictibant is being developed for on-demand treatment of hereditary angioedema (HAE) attacks.
- The RAPIDe-1 trial was a phase 2, randomized, double-blind, placebo-controlled study evaluating deucrictibant's efficacy and safety.
- Participants with HAE type 1 or 2 were given deucrictibant (10 mg, 20 mg, or 30 mg) or placebo to treat attacks.
- Primary endpoint was change in patient-reported composite VAS-3 score from pre-treatment to 4 hours post-treatment.
- Deucrictibant significantly reduced attack severity compared to placebo, with a safety profile similar to placebo.
- The study supports further investigation of oral bradykinin B2 receptor antagonism for HAE treatment.